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patients received medical services to the value of 927 million Euro or 14.2% of total 
reimbursed lump-sums (6.53 billion Euros) in Austria. 224 million Euros fall upon 
medical tumour therapy. With regard to monoclonal antibody therapies, 56 million 
Euros was refunded. ConClusions: The current development in modern cancer 
therapies leads to efficient treatment pathways expressed in higher survival rates, 
reduced hospital days and an improved quality-of-life.
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objeCtives: The objective of this project was to identify the treatment cost of 
malignant ascites from the Italian NHS perspective through a cost-analysis. Three 
reference centers in Italy contributed to this study during year 2012. Methods: 
Three centers (Scientific Institute of Romagna for Cancer Studies and Treatment-
I.R.S.T; Medical Oncology Unit of San Gerardo Hospital; Department of Gynecology 
of University Hospital Agostino Gemelli) were chosen due to the fact that they treat 
a representative sample of patients with malignant ascites in Italy. Each center 
was asked to complete three case report forms: the first identifying the costs for 
the pre-procedure diagnostic tests, the second identifying the specific procedure 
costs (paracentesis) and the third identifying the specific costs due to treatment of 
complications. All these reports had to be completed for the last 5 patients diag-
nosed with malignant ascites in order to prevent selection bias. A total cost for each 
patient was calculated by DRG analysis (standard cost – tariff). The DRG analysis 
assessed: day hospital, admission number, hospitalization, number of hospitaliza-
tion days, principal diagnosis, main procedure/intervention, number of paracentesis 
procedures performed on the same patient with the same diagnosis, DRG type, 
DRG code, refund value for day hospital/ refund value for ordinary hospitaliza-
tion. Results: The analysis shows an average cost of € 1,464.42 per patient with 
malignant ascites using the DRG reimbursement rate (minimum value: € 1,405.63; 
maximum value: € 1,525.37). Analysis using DRG with complications resulted in a 
mean value of € 1,524.84 (minimum value: € 1,429.69; maximum value: € 1,625.55). 
The key cost driver of malignant ascites treatment was the paracentesis proce-
dure. ConClusions: The economic impact of paracenteses is high, especially when 
procedures must be repeated. The reduction in the number of paracenteses could 
reduce the costs while improving the QoL of the patients.
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objeCtives: Colposcopy is an essential part of the screening process for the preven-
tion of cervical cancer by diagnosing and treating precancerous lesions known as 
cervical intra-epithelial neoplasia (CIN). The objective of this study was to assess 
the cost and health impact of using an electrical impedance spectroscopy (EIS) 
device to aid in the diagnosis of precancerous lesions compared to standard colpos-
copy. A threshold for the EIS device that resulted in a similar sensitivity and higher 
specificity than standard colposcopy was used. Methods: Two models to assess 
the cost and health impacts were developed; a short term model representing the 
initial colposcopy treatment pathway and a longer term Markov model that included 
colposcopy follow-up. Sensitivity and specificity of colposcopy were derived from 
the EpiCIN trial of the EIS device. Two referral thresholds were defined in the analy-
sis, the threshold for ‘See and Treat’ on colposcopic impression alone (CI) and a 
lower threshold for referral for biopsy to determine disease presence (DP) prior to 
treatment. Costs of colposcopy were estimated using data from Sheffield Teaching 
Hospitals. Different colposcopy clinic scenarios were modelled to represent the 
different ways colposcopy clinics manage patients. Health related quality of life 
(HRQoL) decrements were applied for colposcopy, biopsy and treatment. One-way 
sensitivity analyses were also conducted. Results: The analysis suggests that the 
use of the EIS device can result in fewer biopsies being taken, a reduction in over-
treatment with an associated small improvement in HRQoL, and a lower colposcopy 
cost per woman with CIN2+ treated for some colposcopy clinic scenarios. The results 
are sensitive to changes in colposcopy costs. ConClusions: The use of the EIS 
device with a higher specificity and similar sensitivity to standard colposcopy has 
the potential to lead to a reduction in the colposcopy cost per woman with CIN2+ 
treated for some clinic scenarios.
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objeCtives: To estimate the epidemiological and economic benefits of a quad-
rivalent HPV vaccination in girls and boys compared with vaccination only in girls 
in Spain. Methods: A population-based compartmental dynamic transmission 
model of HPV developed in the US was partially adapted to the Spanish setting 
updating epidemiological data of HPV related diseases, the vaccination coverage and 
direct costs of the diseases. The analysis was performed from the National Health 
System (NHS) perspective. The strategy of cervix cancer screening (CCS) and vac-
cination of only girls from 11 to 26 years (S1) was compared to CCS and vaccination 
of girls and boys from 11 to 26 years (S2) with the quadrivalent vaccine. Assuming 
the duration of protection against vaccine HPV types is lifetime, the results over a 
100-year time horizon, were estimated applying a discount of 3% on costs. In order 
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objeCtives: Lung cancer is the most frequently diagnosed oncologic disease world-
wide, annually diagnosed in nearly 1.4 million patients. In 2010, the incidence in 
men was 89.7 per hundred thousand people (in 1996, it was 102.3), while in women 
35.2 (against 22.9 in 1996). The severity of the disease is also reflected by the high 
mortality rate, which was 74.8 per hundred thousand people in men and 27.4 in 
women in 2010. Methods: Identifying the costs spent by a clinic/hospital is dif-
ficult in the Czech Republic, as the majority of hospitals work with cost related 
data in the “confidential” mode. The costs were estimated and verified based on 
expert opinions of pulmonologists, oncologists, head physicians and staff mem-
bers of technical and economic departments of five pneumo-oncologic centres and 
university hospitals in this study. Results: Totally 32 procedures (process maps) 
were identified in lung cancer treatment (10 in diagnostic, 22 in therapeutic pro-
cesses). Each procedure consists of diagnostics, therapy and subsequent monitor-
ing of patients. Costs for respective steps were assessed, and total costs for each 
therapeutic scheme were calculated. ConClusions: The calculations imply that 
treatment costs significantly differ depending on the selected diagnostic/ therapeu-
tic procedure. The setting of the reimbursement system generates different stimuli 
for providers who may reach both positive and negative balances. This fact may 
have an effect on economic results leading, in its consequence, to the preference 
of alternatives more suitable in terms of reimbursement regardless of the optimum 
procedures for a specific patient.
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objeCtives: To identify the chemotherapeutic treatment patterns and associated 
costs in patients with chronic lymphocytic leukemia (CLL) in the Private Healthcare 
System. Methods: A retrospective analysis of the Orizon database, containing 
inpatient and outpatient claims data of a pool of 102 HMOs (34% of the total Private 
Health System), from January 2009 to December 2012 was conducted. Eligibility cri-
teria were patients starting CLL (ICD-10 code C911) chemotherapy treatment from 
April 2009 to December 2012. This cohort of patients was followed until December 
2012, death or loss of follow-up. Chemotherapy regimens were identified based on 
the agents reported in the claims. Line of treatment was defined based on mean-
ingful interruption (> 6 months) and/or change in the chemotherapy regimen. 
Descriptive statistics (average, standard deviation and percentage) of treatment 
regimens, duration of treatment and costs were performed. Results: A total of 163 
patients representing 859 cycles of chemotherapy met eligibility criteria; 43.6% of 
the patients underwent more than one line of treatment, with total chemotherapy 
costs of R$84,979.63 per patient. The three most widely used chemotherapy regimen 
were: fludarabine, cyclofosfamide and rituximab (FCR), used in 81 (54.9%) patients 
with average treatment duration of 3.54 cycles and total costs of R$69,241.91 per 
patient; rituximab monotherapy, used in 44 (27.0%) patients, with average treatment 
duration of 4.05 cycles and total costs of R$59,543.12 per patient; and fludarabine 
and cyclofosfamide (FC), used in 19 (11.7%) patients, with average duration of 2.22 
cycles and total costs of R$7,075.95 per patient. Chemotherapy drugs accounted 
for 72.8% of the total costs, followed by other medicines (11%), disposable devices 
(5.5%) and hospital facility fees (5.0%). ConClusions: FCR is the standard of care 
in CLL patients treated in the Brazilian Private Health System, and almost half of 
the patients undergo more than one treatment line, creating a significant financial 
burden to private payers.
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objeCtives: In Austria, 38,000 people are yearly diagnosed with cancer, which 
is the world’s leading cause of death (Austria: 19,547), followed by heart disease 
and stroke. Advances in early detection, prevention and treatment have led to 
decreasing cancer death and more favorable outcomes. Moreover, significant 
increases in the cost of cancer care have come in parallel with these advances. 
The cost factor related to modern cancer treatment is increasingly a matter of 
debate. Hence, the aim of the analysis was to evaluate the cost of cancer expressed 
as reimbursed lump-sums of the DRG system, number of inpatients stays and 
Length-of-Stay (LOS) in the inpatient setting to bring more transparency in the 
discussion and bridge the information-gap. Methods: We performed a retrospec-
tive claim-based analysis with Austrian DRG-System (LKF Leistungsorientierte 
Krankenanstaltenfinanzierung) data. The DRG-System is based on ICD-10 codes. 
Payment consists of one or several case-based lump-sums. Our analysis included 
all cancer hospital admissions. The cost-evaluation is based on the refunded 
lump-sums of the DRG-System for the year 2011. Results: In 2011, 353,883 
inpatient stays with a diagnosis of cancer were monitored. Hospital stays due to 
cancer accounts for 14% of the entire inpatient stays in Austria. The average LOS 
in cancer patients was 4.35 days and was associated with average costs per stay 
of 3,730 Euros. Compared with the total number of admissions these numbers 
are below average (LOS: 5.43; costs per stay: 3,949 Euros). Furthermore, cancer 
